



enterprise europe

Boletín de Oportunidades de Cooperación:

Biotecnología y Salud

Boletín nº 137

Noviembre 2015

enterprise europe

Índice

Referencia	Título	Tipo Perfil
TOAT20150928001	Ergometers suitable for dynamic stress tests within magnetic resonance tomography	Technology Offer
TOES20151007009	Novel non-peptidic calcineurin inhibitors immunosuppressants	Technology Offer
TOSK20151016001	Antigens for specific detection of antibodies against <i>Coxiella burnetii</i> , and some chlamydial and rickettsia species with practical use in agriculture, livestock production, slaughterhouses, milk production, animal skin-processing and veterinary industries	Technology Offer
TRIN20150703001	iDecide	Technology Request

Technology Offer

Ergometers suitable for dynamic stress tests within magnetic resonance tomography

Summary

An Austrian SME specialized in medical devices has developed ergometers compatible with all MR (magnetic resonance) systems. The diagnostic pedal allows the physician to measure various physiological parameters while the patient is under defined physical stress. There are various fields of application in medicine or pharmaceutical compatibility examinations. The SME seeks partners interested in license agreements and research cooperation for further development.

Creation Date	02 October 2015
Last Update	06 October 2015
Expiration Date	05 October 2016
Reference	TOAT20150928001

Details

Description

In contrast to conventional (state-of-the-art) methods, with the use of the developed pedals the patients do not require drugs, which could lead to complications and other misleading indications. Furthermore these pedals are compatible with all MRI systems (up to 9 Tesla and higher) because all of the components used contain only non-magnetic materials and have been tested for their magnetic resonance suitability.

The Austrian SME is specialized in the development and production of highly accurate medical diagnostic pedals suitable for stress MRI (Magnetic Resonance Imaging) of the myocardium and the musculoskeletal system. By using these advanced MRI techniques, pathological alterations can be detected during physiological stress, which may be otherwise masked and therefore underdiagnosed during rest.

The company's products enable the investigation of blood flow, motility and metabolism as well as structural alteration of the myocardium during a defined stress. Examinations can therefore be easily performed and repeated, which make the tools extremely useful for testing therapeutic strategies.

These ergometers allow the medical practitioner to obtain information more quickly and with greater accuracy in order to pinpoint medical problems which might not be detected without physical stress.

The main diagnostic focus is the evaluation of coronary heart disease, peripheral arterial disease, muscle fatigue disorders, degenerative disorders of the joints and spine, as well as monitoring training success in athletes.

The developed MRI compatible ergometer use the most advanced technology to simulate stress

in an MRI bore, to mirror routine daily situations or training conditions. Thanks to these new diagnostic tools, musculoskeletal functions can be measured dynamically. Physiological parameters are then digitally recorded to clarify symptoms in high-risk patients, geriatrics and sports medicine.

The system consists of a basic platform, which can be combined with different modules depending on the examination to be carried out. On request, the company can also develop and deliver individual solutions according to customer specifications.

The SME seeks partners interested in license agreements for international distribution and is looking for research cooperation's for further development of the devices and the method.

Advantages and Innovations

- Measurement system for high-field magnetic resonance tomography under physical stress.
- Modular system for different fields of medical examination.
- Advanced diagnostic options for other medical examinations.
- Early diagnosis of diseases.
- magnetic resonance suitable ergometer" compatible with all Tesla fields and MRI vendors
- different diagnose under stress than in rest
- clear diagnoses as well as differential diagnoses
- quick and easy to use in a daily clinical routine
- pre & post-operative training assessment
- more accurate measurements in less time
- low-cost examinations
- non-invasive and pain-free examinations
- extension of the diagnostic spectrum

Stage of Development

Already on the market

IPR Status

Patents granted

Comment Regarding IPR status

Patent granted in China,USA and EU, pending in India.

Profile Origin

National R&D programme

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

Rocio Muñoz Maestre

Email

rocio.munoz.maestre@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English

German

Client Country

Austria

Partner Sought

Type and Role of Partner Sought

- Type of partner sought:

Industry: Strategic Partner, Distribution Partner, Development Partner

Scientific Partner: R&D Institute, University for research (no contract research)

- Specific area of activity of the partner:

Radiology and angiography, cardiology, neurology, orthopaedics, sports medicine, vascular surgery or pharmaceutical industry, MR producers and radiology industry in general.

- Task to be performed by the partner sought:

Scientific studies academic research (no contract research), further developments, strategic partnership.

Type of Partnership Considered

License agreement

Research cooperation agreement

Technology Offer

Novel non-peptidic calcineurin inhibitors immunosuppressants.

Summary

A Catalan computational medicine research group in collaboration with a cellular signalling group has developed new compounds acting as calcineurinic inhibitor immunosuppressants with less side effects compared to the current immunosuppressive treatment. The groups are looking for pharmaceutical companies for license or technical cooperation agreement to improve and further develop the compounds.

Creation Date	07 October 2015
Last Update	07 October 2015
Expiration Date	04 April 2016
Reference	TOES20151007009

Details

Description

Cyclosporin A and Tacrolimus are the cornerstone of immunosuppressive therapy. Many patients need such immunosuppression for long periods of administration: people suffering autoimmune diseases, patients with a transplanted organ who need to avoid the rejection, etc. Despite their benefits, unfortunately such drugs are related to important side effects: neurotoxicity, renal dysfunction, hypertension and diabetes.

Two Catalan research groups focused on computational medicine and cellular signalling have identified a family of compounds that also target calcineurin (CN) and do not disrupt other signalling pathways, revealing their therapeutic immunosuppressant potential without the current side effects.

With the virtual and in vitro screening, four hit molecules shown successful CN interaction and inhibition of cytokine production and proliferation of human activated peripheral blood CD4+ lymphocytes, revealing their therapeutic potential as immunosuppressant agents. Cytotoxicity assays in human cells show no toxicity of the hit compounds.

The groups are seeking pharmaceutical companies working on immunosuppressive therapies for license or technical cooperation agreement to improve the compounds and continue with the preclinical phase.

Advantages and Innovations

- Alternative to current immunosuppressants characterized in that the compounds discovered do not interfere in other calcineurin-mediated pathways.
- No side effects are expected.

- Current immunosuppressant drugs are big molecules (peptides). The proposed immunosuppressants are simple small molecules. A good bioavailability pattern is expected. No cytotoxicity was observed.

- Oral administration.

Stage of Development

Under development/lab tested

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

European patent application

Profile Origin

Other European R&D programme

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

Rocio Muñoz Maestre

Email

rocio.munoz.maestre@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Bio Chem Tech

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Spanish

Client Country

Spain

Partner Sought

Type and Role of Partner Sought

- Type of partner sought: pharmaceutical companies
- Specific area of activity of the partner: immunosuppressive therapies
- Task to be performed by the partner sought: improve the compounds and perform in vitro and in vivo tests. These preclinical assays could be performed in collaboration with the groups under technical cooperation agreement.

Type of Partnership Considered

License agreement
Technical cooperation agreement

Technology Offer

Antigens for specific detection of antibodies against *Coxiella burnetii*, and some chlamydial and rickettsia species with practical use in agriculture, livestock production, slaughterhouses, milk production, animal skin-processing and veterinary industries

Summary

*A Slovak institute has developed new highly purified corpuscular antigens of *Coxiella burnetii*, and some chlamydial and rickettsial species. They were designed for accurate measurement of antibodies against these bacteria in serum, plasma and milk samples of animals and humans. An efficient corpuscular vaccine for prophylaxis against coxiellosis in livestock is also available. These products are open for license and/or joint venture.*

Creation Date	16 October 2015
Last Update	24 October 2015
Expiration Date	23 October 2016
Reference	TOSK20151016001

Details

Description

A Slovak institute active in virology and microbiology has developed new highly purified corpuscular antigens enabling rapid, simple, sensitive and specific detection of antibodies against *Coxiella burnetii* and some chlamydial and rickettsial species in serum, plasma and milk samples of animals and in human.

Antigens are white or slightly yellow, uniformly turbid suspensions of highly purified bacterial cells in phosphate buffered saline with thiomersal or phenol as a preservative. However, a sediment may be formed after a longer period of storage it can easily be re-suspended by shaking.

Here is the list of developed antigens:

Antigens for Q fever serodiagnostics:

Complement fixation (CF) test

- *Coxiella burnetii* phase I antigen for CF test
- *Coxiella burnetii* phase II antigen for CF test

Enzyme-linked immunosorbent assay (ELISA)

- *Coxiella burnetii* phase I antigen for ELISA test

- Coxiella burnetii phase II antigen for ELISA test

Antigens for chlamydiosis serodiagnostics

Complement fixation (CF) test

- Chlamydia psittaci antigen for CF test

- Chlamydia abortus antigen for CF test

Enzyme-linked immunosorbent assay (ELISA)

- Chlamydia psittaci antigen for ELISA test

- Chlamydia abortus antigen for ELISA test

Antigens for spotted fever group rickettsiosis serodiagnostics

Enzyme-linked immunosorbent assay (ELISA)

- Rickettsia conorii antigen for ELISA test

- Rickettsia akari antigen for ELISA test

- Rickettsia slovaca antigen for ELISA test

Domain of application of this technology:

Professions at high exposition risk: personnel in agriculture, life stock production, slaughterhouses, milk production, animal skin-processing industry, veterinarians and laboratory personnel.

The research institute is looking for cooperation via joint venture agreement (the partner for this specific technological project is sought) or via license agreement (the research institute is offering a license). These types of cooperation have been chosen because they are fitting today's need of the company in the best possible way.

Advantages and Innovations

Rapid antigen detection testing would allow a more rational use of antibiotics and would prevent adverse effects of antibiotics on the patient, antibiotic resistance emergence and the growth of inefficient health expense.

Stage of Development

Field tested/evaluated

IPR Status

Secret Know-how

Profile Origin

Private (in-house) research

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

Rocio Muñoz Maestre

Email

rocio.munoz.maestre@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

R&D Institution

Year Established

1953

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Slovak
Czech

Client Country

Slovakia

Partner Sought

Type and Role of Partner Sought

- Type of partner sought: The Slovak research institute is looking especially for these kind of partners: institutes and institutions - hospitals, health centres, veterinary institutes, regional veterinary stations, etc.

- Field of activity: health, veterinary, agriculture

- Role of partner: The research institute is looking for cooperation via joint venture agreement (the research institute has a specific technological project and is looking for a partner) or via license agreement (the research institute is offering a license).

Type and Size of Partner Sought

SME 11-50,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

License agreement
Joint venture agreement

Technology Request

iDecide

Summary

An Indian startup company is developing a mobile healthcare application with over 25 modules including clinical record management and patient education. The company is looking for joint venture agreement, research cooperation agreement or services cooperation agreement. The application would increase patient provider interaction and strengthen the patient interaction enabling patient to be a good negotiator with providers.

Creation Date	03 July 2015
Last Update	07 October 2015
Expiration Date	06 October 2016
Reference	TRIN20150703001

Details

Description

The company is a startup that promotes mobile health products. The company is a public limited company started by 7 public health experts for the promotion of technology for bringing patient engagement in healthcare.

The company specializes in patient education, information technology (IT) for health, mobile phone technology for health, developing patient education materials. The product iDecide is a mobile phone application which facilitates patient provider interaction with the help of smart phone. The product needs to be downloaded and subscriptions can be made as subscriber or provider. Subscribers are mostly patients and general public. Providers include doctors to small clinics to medical colleges across the world. The patient choices are enhanced by facilitating provider enrollment into the app from various categories of providers. This will ultimately facilitate provider competition which will benefit the patients in terms of cost and quality. The basic idea is to develop an interactive healthcare application that can be downloaded to any mobile device/ iPad/ tablet/ laptop.

The collaboration can be either a joint venture agreement, research cooperation or services cooperation. The partner should have capacity in software development, mobile app development, marketing strategy development and working with smart cards.

The uniqueness of the product is that the patient has an option to become experts and earn by giving opinion on service on the app. Patients thus have an opportunity to get financial return. The expertise that the project looks forward to develop is electronic clinical data management for diagnostic management, clinical data mining for disease surveillance and illness prediction for early prevention and cost reduction through promoting patient centric and accountable healthcare systems.

Technical Specification or Expertise Sought

The company is looking for marketing support, joint marketing, investment (equity), technology support and local market research support from the partner of interest. The partner should be able to customize the product according to the country requirement, inpatient remote monitoring developing sensors for treatment follow up.

Stage of Development

Available for demonstration

Comments Regarding Stage of Development

The product is under development and the first phase demo is to be available soon in a couple of months. The phase II with more modules and services will be worked after the launch of the phase I application. Phase II will digitize most of the health care transaction including curative and preventive and promote care services.

IPR Status

Copyright

Comment Regarding IPR status

IPR will be shared with new ventures who invest further funds.

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

Rocio Muñoz Maestre

Email

rocio.munoz.maestre@juntadeandalucia.es

Open for EOI : **Yes**

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME 11-49

Year Established

2012

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English

Client Country

India, Republic of

Partner Sought

Type and Role of Partner Sought

Looking to collaborate with industry, innovators, marketing and producer industries, information technology (IT) consulting firms.

The type of activities expected from the partner of interest include health education material development, software development, developing sensors, product marketing and developing partnerships.

Through joint venture agreement, research cooperation agreement or services agreement, the company is seeking to develop this mobile phone app in android, windows and others.

Type and Size of Partner Sought

University, R&D Institution, SME <10, >500 MNE

Type of Partnership Considered

Services agreement
Joint venture agreement
Research cooperation agreement